Dr. Frank Song, the Founder and Chief Executive Officer of Eminence, possesses over two decades of extensive experience in the pharmaceutical and biotech industries. His broad expertise encompasses various domains, such as the establishment of stable cell lines, process enhancement, technology transfer, GMP clinical manufacturing, and the diligent preparation of Investigational New Drug (IND) applications. His profound understanding and specialized abilities have been instrumental in the advancement of numerous biologics in both the United States and Europe.
Before founding Eminence, Dr. Song occupied pivotal roles at globally recognized and pioneering biopharmaceutical companies, including Regeneron, Astellas, and EMD Millipore (now part of Sigma Millipore). In these capacities, he spearheaded upstream process development and Chemistry, Manufacturing, and Controls (CMC) activities, achieving significant milestones, including the notable accomplishment of leading the cell line development for Regeneron's inaugural FDA-approved drug.
During his subsequent tenure exceeding a decade at Ambrx, Dr. Song, serving as the Director of Upstream Process Development, skillfully guided numerous R&D projects through various phases. He was instrumental in establishing technology platforms, including a high-expression platform for site-specific Antibody-Drug Conjugates (ADCs). His proficient leadership facilitated the advancement of several ADC projects into clinical trials in China, the United States, and Australia.
Dr. Song is not only a respected figure in the industry but also a distinguished academic, with numerous publications in internationally acclaimed journals. As the recipient of more than ten multinational invention patents, he has been at the vanguard of several core technologies in the realm of industrial cell culture. His leadership prowess is further highlighted by his contribution to six IND applications in the United States and one in China.
Dr. Song's academic credentials include an M.S. in Pharmacology from St. John's University and an M.D. from Shanghai Second Medical University (now known as Shanghai Jiao Tong University).
